Africa not ‘walking away’ from AstraZeneca vaccine, says disease control body
The African Union’s disease control body said on Thursday that it was not “walking away” from AstraZeneca’s COVID-19 vaccine, after trial data
showed it had greatly reduced efficacy against the coronavirus variant dominant in South Africa.
African countries are due to receive 100 million doses of the AstraZeneca shot this year under an AU vaccine plan.
For more coronavirus news, visit our dedicated page.
Africa CDC Director John Nkengasong told a news conference that more work needed to be done to understand how the vaccine worked against the more contagious 501Y.V2 variant first identified in South Africa late last year.
For all the latest headlines follow our Google News channel online or via the app
South Africa has paused the rollout of AstraZeneca shots to health workers and said on Wednesday it could seek to sell or swap doses of the vaccine.
Nkengasong added that six countries other than South Africa had reported the presence of the variant. This has alarmed health experts who have raised concerns about its ability to potentially evade the immune response generated by prior exposure to the coronavirus or vaccines.
The six countries are Botswana, Comoros, Ghana, Kenya, Mozambique and Zambia.
“For countries that have not reported the circulation of the 501Y.V2 variant, we recommend that they proceed with the rollout of the AstraZeneca vaccine,” Nkengasong said.
“For countries that have reported the circulation of the 501Y.V2 variant, we recommend the acceleration of their preparedness to introduce all vaccines that have received emergency use authorization or approval by regulatory authorities. Consideration should be given to the effectiveness of the vaccine against the 501Y.V2 variant.”
Nkengasong said the Africa CDC would be doing its own evaluations of the AstraZeneca vaccine across multiple countries and that no countries had said they would not be using the vaccine.
He added that the AU was in talks with Johnson & Johnson on the supply of more COVID-19 vaccines, beyond the 120 million doses that already feature in its vaccine plan.
Separately, Kenya said it would move ahead with plans to use the AstraZeneca vaccine.
South Africa suspends AstraZeneca COVID-19 vaccine drive
AstraZeneca vaccine being tweaked to fight S. Africa variant
What we know about the South African coronavirus variant
What we know about the South African coronavirus variantSouth Africa halted the planned rollout of the COVID-19 vaccine developed by AstraZeneca and Oxford University after data showed it gave minimal ... Coronavirus
South Africa to give health workers Johnson & Johnson vaccine as part of studySouth Africa’s health minister said on Wednesday that the country would vaccinate health workers with Johnson & Johnson’s COVID-19 vaccine in the form ... Coronavirus
India orders more AstraZeneca doses despite South Africa haltIndia said on Tuesday it had no concerns over the efficacy of the AstraZeneca COVID-19 vaccine despite South Africa putting it on hold, and ordered 10 ... Coronavirus
Austria tries to contain S. African coronavirus variant outbreak by voluntary meansAustria on Monday opted against placing the whole Alpine province of Tyrol under quarantine to contain an outbreak of the so-called South African ... Coronavirus
UK says AstraZeneca vaccine prevents COVID-19 death as South Africa halts shotsThere is no evidence that the AstraZeneca vaccine does not prevent death or serious illness, and South Africa has only imposed a temporary halt on ... Coronavirus
South Africa suspends AstraZeneca COVID-19 vaccine driveSouth Africa has suspended plans to inoculate its front-line health care workers with the Oxford-AstraZeneca vaccine after a small clinical trial ... Coronavirus
AstraZeneca vaccine being tweaked to fight S. Africa variantDevelopers of the Oxford-AstraZeneca vaccine expect to have a modified jab to cope with the South Africa coronavirus variant by autumn, the vaccine’s ... Coronavirus